

CLAIMS

1. A pharmaceutical composition for parenteral administration, which comprises a peptide and dimethyl sulfone.
- 5 2. A pharmaceutical composition according to claim 1, wherein the amount of dimethyl sulfone is of from 40 to 400 mM.
3. A pharmaceutical composition according to claim 2, wherein amount of dimethyl sulfone is of from 125 to 350 mM.
- 10 4. A pharmaceutical composition according to claim 1, wherein the composition is a solution.
5. A pharmaceutical composition according to claim 1, wherein the composition is a suspension.
- 15 6. A pharmaceutical composition according to claim 1, which is suitable for administration by injection or infusion.
7. A pharmaceutical composition according to claim 6, which is suitable for subcutaneous administration.
- 20 8. A pharmaceutical composition according to claim 6, which is suitable for intramuscular administration.
- 25 9. A pharmaceutical composition according to claim 6, which is suitable for intravenous administration.
10. A pharmaceutical composition according to claim 1, which is suitable for pulmonal administration.
- 30 11. A pharmaceutical composition according to claim 1, which is suitable for ophthalmic administration or topical administration.

12. A pharmaceutical composition according to claim 1, wherein the peptide is human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoietin (EPO), glucagon, interleukin, such as interleukin-2 (IL-2), interferon- α or interferon- β , or an analogue thereof, or a derivative of any such peptide or analogue.

5

13. A pharmaceutical composition according to claim 12, wherein the peptide is human insulin or an analogue thereof, or a derivative of human insulin or the human insulin analogue.

14. A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

10

15. A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

15

16. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

17. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

20

18. A pharmaceutical composition according to claim 13, wherein the peptide is N ^{ϵ B29}-tetradecanoyl des (B30)-human insulin.

19. A pharmaceutical composition according to claim 13, wherein the peptide is

25 Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. A pharmaceutical composition according to claim 13, wherein the peptide is N ^{ϵ B29}-litolchloyl- γ -glutamyl des (B30)-human insulin.

30 21. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(8)-human GLP-1.

22. A pharmaceutical composition according to claim 12, wherein the peptide is Arg(34), N- ϵ -(γ -Glu(N- α -hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

35

23. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(2)-human GLP-2.